Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
Publication
, Other
Karkouti, K; Levy, JH
Published in: Anesth Analg
October 2011
Duke Scholars
Published In
Anesth Analg
DOI
EISSN
1526-7598
Publication Date
October 2011
Volume
113
Issue
4
Start / End Page
711 / 712
Location
United States
Related Subject Headings
- Ticlopidine
- Recombinant Proteins
- Platelet Aggregation Inhibitors
- Male
- Humans
- Hemostatics
- Hemostasis
- Hemorrhage
- Factor VIIa
- Clopidogrel
Citation
APA
Chicago
ICMJE
MLA
NLM
Karkouti, K., & Levy, J. H. (2011). Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg. United States. https://doi.org/10.1213/ANE.0b013e318228c6a9
Karkouti, Keyvan, and Jerrold H. Levy. “Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.” Anesth Analg, October 2011. https://doi.org/10.1213/ANE.0b013e318228c6a9.
Karkouti K, Levy JH. Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Vol. 113, Anesth Analg. 2011. p. 711–2.
Karkouti, Keyvan, and Jerrold H. Levy. “Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.” Anesth Analg, vol. 113, no. 4, Oct. 2011, pp. 711–12. Pubmed, doi:10.1213/ANE.0b013e318228c6a9.
Karkouti K, Levy JH. Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg. 2011. p. 711–712.
Published In
Anesth Analg
DOI
EISSN
1526-7598
Publication Date
October 2011
Volume
113
Issue
4
Start / End Page
711 / 712
Location
United States
Related Subject Headings
- Ticlopidine
- Recombinant Proteins
- Platelet Aggregation Inhibitors
- Male
- Humans
- Hemostatics
- Hemostasis
- Hemorrhage
- Factor VIIa
- Clopidogrel